Clarity Pharmaceuticals Ltd

Clarity Pharmaceuticals Ltd is an Australian-based clinical-stage radiopharmaceutical company dedicated to developing next-generation products to improve treatment outcomes for individuals with cancer. Headquartered in Eveleigh, Australia, the company focuses on advancing innovative diagnostic and therapeutic radiopharmaceutical products toward commercialization.

The company's core business revolves around its proprietary SAR Technology platform, which utilizes the "perfect pairing" of copper isotopes: copper-64 (Cu-64) for imaging and diagnosis, and copper-67 (Cu-67) for therapy. Key products in its clinical development pipeline include SAR-bisPSMA for prostate cancer, SAR-Bombesin for various cancers including prostate, breast, and ovarian, and SARTATE for neuroblastoma and neuroendocrine tumors (NETs). This platform aims to address unmet clinical needs across a range of cancer indications.

Clarity Pharmaceuticals is actively progressing towards commercialization, marked by recent strategic developments. In April 2026, the company signed a Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA with Nucleus RadioPharma and a large-scale Manufacturing Supply Agreement for copper-64 with Theragenics in March 2026, expanding its production capacity and geographic reach. Michelle Parker was appointed CEO in October 2024, joining Executive Chairperson Dr. Alan Taylor in leading the company's efforts to bring its Targeted Copper Theranostic (TCT) platform to market. The company also successfully completed a $203 million institutional placement in July 2025 to fund its clinical trials.